Abiomed
Clinical trials sponsored by Abiomed, explained in plain language.
A medical device company specializing in heart pumps, now part of Johnson & Johnson.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Heart pump may boost survival in complex stenting Results expected Oct 2026 (estimated)
- New heart pump aims to make risky artery procedures safer Results expected Oct 2026 (estimated)
- New heart pump aims to make risky artery procedures safer Results expected Dec 2026 (estimated)
- Heart pump data study aims to sharpen shock monitoring Results expected Jun 2027 (estimated)
-
Heart pump may boost survival in High-Risk surgery patients
Disease control CompletedThis study tests whether using the Impella 5.5 heart pump during and after heart surgery improves outcomes for 100 patients with severely weakened hearts. The pump supports blood flow, aiming to reduce death, stroke, kidney failure, and heart failure after surgery. Participants m…
Sponsor: Abiomed Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Vein-Blocking device shows promise for heart failure patients
Symptom relief CompletedThis study tested a device called preCARDIA that temporarily blocks a large vein in the chest to help patients with sudden, severe heart failure. The goal was to see if it is safe and can help remove excess fluid when standard treatments are not working. The study included 60 adu…
Sponsor: Abiomed Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC